Newsroom
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he discusses sustainability in laboratories and the interconnectivity of environmental health and public health.
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.
Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.
In recent articles, Mayo Clinic Laboratories emphasizes the transformative potential of recognizing and leveraging the capabilities of a hospital laboratory. With more touchpoints than any other outpatient service line, the laboratory is full of opportunity to enhance local healthcare delivery and bolster a hospital’s financial stability.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he describes the untapped potential of hospital laboratories and how health systems can maximize the value of their labs.
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins “Becker’s Healthcare Podcast” to discuss organizational alignment during times of change. She shares her expertise on creating transparency, fostering open communication, and using data to stay on track with business goals.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his first article, Dr. Morice reflects on the diagnostic landscape and predicts trends that could influence the market in 2024.
Mayo Clinic Laboratories now offers the first preeclampsia-specific test (Mayo ID: PERA) that can be used to stratify patients into low or high-risk categories, indicating whether a patient is at risk for developing preeclampsia with severe features. With this information, clinicians can make more informed decisions about hospitalization, monitoring, more frequent checkups, and even early delivery.
Globally, five million deaths are associated with bacterial antimicrobial resistance each year, but the complexity of the issue is there is no single solution because we need to use antibiotics. It’s about finding a different way to live with it.
Mayo Clinic Laboratories is grateful for the opportunity to serve you and other healthcare professionals around the globe in providing critical answers and actionable insights.
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.
Top highlights include: Government to launch $300M Azlheimer's research database, new COVID variant XBB.1.16 spotted in 18 US states, and novel treatment shows promise against rare cancer in kids.
Today's Highlights Include: US FDA seeks to allow salt substitutes in everyday foods, radioactive water leaks at Minn. nuclear plant for 2nd time, and pushback grows over mental health impacts of social media.